SCHEMBL831650

SCHEMBL831650

Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(=O)(=O)C3CC3)n(Cc3cc4ccccc4nc3Cl)c2cc1Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.65
KMT2A Q03164 8/20 0.35
AURKA O14965 2/20 0.34
TPX2 Q9ULW0 2/20 0.34
RCE1 Q9Y256 1/20 0.34
TRPM4 Q8TD43 1/20 0.33
PTGER4 P35408 1/20 0.33
FAAH O00519 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 2/20 0.32
KDM4E B2RXH2 3/20 0.32
ALDH1A1 P00352 3/20 0.32
SCN2B O60939 2/20 0.32
SCN1A P35498 2/20 0.32
SCN1B Q07699 2/20 0.32
SCN9A Q15858 2/20 0.32
GAA P10253 1/20 0.31
CYP1A2 P05177 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831646 0.94 CYP2C8 (0.74) CYP2C8KMT2AAURKATPX2RCE1
SCHEMBL831122 0.91 CYP2C8 (0.59) CYP2C8KMT2AAURKATPX2RCE1
SCHEMBL832432 0.91 CYP2C8 (0.69) CYP2C8KMT2ARCE1FAAHMEN1
SCHEMBL862278 0.90 CYP2C8 (0.64) CYP2C8KMT2AAURKATPX2RCE1
SCHEMBL832851 0.89 CYP2C8 (0.66) CYP2C8KMT2ARCE1FAAHMEN1
SCHEMBL831547 0.88 CYP2C8 (0.56) CYP2C8KMT2AAURKATPX2RCE1
SCHEMBL832872 0.87 CYP2C8 (0.60) CYP2C8KMT2AAURKATPX2RCE1
SCHEMBL831648 0.86 CYP2C8 (0.56) CYP2C8KMT2ARCE1PTGER4FAAH
SCHEMBL12673764 0.85 CYP2C8 (0.86) CYP2C8KMT2ARCE1FAAHMEN1
SCHEMBL13905194 0.85 CYP2C8 (0.61) CYP2C8KMT2AAURKATPX2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885KMT2A 321/4885AURKA 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.